EGFR and glioblastoma: First-generation small molecule EGFR inhibitors (gefitinib, erlotinib, and lapatinib) block the ATP site of the tyrosine kinase domain and have reasonable tolerability in GBM patients, but do not increase overall survival [50,51,52,53,54,55,56,57,58,59,60,61,62,63].